Center-Authored Papers

Filters: Keyword is Prostatic Hyperplasia  [Clear All Filters]
K
Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD.  2010.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 70(6):584-90. Abstract
Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM.  2008.  Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 167(8):925-34. Abstract
Kristal AR, Schenk JM, Song YJ, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM.  2008.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 168(12):1416-24. Abstract
L
Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS et al..  2008.  WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(5):1397-406. Abstract
M
Marks LS, Mostaghel EA, Nelson PS.  2008.  Prostate tissue androgens: history and current clinical relevance.. Urology. 72(2):247-54. Abstract
McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J et al..  2008.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.. Clinical chemistry. 54(1):44-52. Abstract
N
Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR.  2008.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.. The Prostate. 68(13):1477-86. Abstract
Q
Qian DZ, Huang C-Y, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS et al..  2009.  Prostate cancer-associated gene expression alterations determined from needle biopsies.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(9):3135-42. Abstract
S
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM.  2009.  Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 69(12):1303-11. Abstract
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM.  2010.  Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 171(5):571-82. Abstract
Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M, Greenberg NM.  2008.  Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.. Cancer research. 68(9):3495-504. Abstract